Exhibit 10.36


Memorandum
of Understanding (MoU)


Between


Curetis
GmbH, Ares Genetics GmbH and MGI Tech Co., Ltd.


Preamble


Progress
in the prevention and treatment of infectious diseases has vastly improved the survival chances and quality of life of patients
across the globe. In recent years however, spreading of antimicrobial resistance through indiscriminate use of antibiotics has
become one of the most severe threats to modern medicine. Better and faster ways to diagnose microbial infections are key to a
more targeted use of antibiotics to slow down the development of resistance to current and future drugs.


Rapid
adoption of next generation sequencing (NGS) in genomic medicine has been driven by low cost, high throughput sequencing and rapid
advances in our understanding of the genetic bases of human diseases and associated pathogens. Today, NGS is dominating the sequencing
space in genomic research, and quickly entering clinical practice, specially in pre-natal screening and cancer diagnostics. While
already a key technology in infectious disease research today, the unique features of NGS, advancement of NGS technology, NGS
workflow integration and automation as well as NGS affordability, make NGS more and more applicable to clinical diagnostics of
infectious diseases.


With
this Memorandum of Understanding (MoU), Curetis and MGI want to express their intent to collaborate in the advancement of Molecular
Diagnostics and NGS Technology for the diagnosis of infectious diseases and antimicrobial resistance.


 


THE
UNDERSIGNED,


		1.	Curetis
                                         GmbH, a corporation of Germany having a place of business at Max-Eyth-Str. 42, 71088
                                         Holzgerlingen, Germany (hereinafter referred to as “Curetis”)



		2.	Ares
                                         Genetics GmbH, a corporation of Austria having a place of business at Karl-Farkas-Gasse
                                         18, A-1030 Vienna, Austria (hereinafter referred to as “Ares”)



		3.	MGI
                                         TECH CO., LTD. (A part of BGI Groups), an entity of China, having a place of business
                                         at No. 11, Beishan Industrial Zone, Yantian District, Shenzhen 518083, P.R.C (hereinafter
                                         referred to as “MGI”)



 


WHEREAS:


		1.	Curetis
                                         is a molecular diagnostics company which focuses on the development and commercialization
                                         of reliable, fast and cost-effective products for diagnosing severe infectious diseases.
                                         The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic
                                         resistance marker detection in only a few hours, a process that today can take up to
                                         days or even weeks with other techniques.



 


 




    	1 




    	 



    


Curetis
established Ares, a wholly-owned subsidiary of Curetis GmbH in Vienna, Austria. Ares is dedicated to maximizing the
R&D and related scientific and business opportunities of the GEAR assets acquired from Siemens in 2016 for the entire Curetis
Group.


		2.	BGI-Shenzhen
                                         Co., Ltd (hereinafter referred to as “BGI Group”), BGI Group undertook
                                         1% part of the Human Genome Project, have accomplished many research achievements in
                                         multiple fields. Comprehensive research platforms and database was established and a
                                         series of software for the analysis of high-throughput genetic sequencing was developed,
                                         BGI Group have contributed more than 50% of global genetic sequence data, 70% agricultural
                                         organisms’ genetic sequence data. BGI Group now is the largest genome research
                                         center all over the world and the sequencing giant in China.



MGI
Tech Co., Ltd (hereinafter referred to as “MGI”), BGI Group established MGI, a wholly-owned subsidiary
of BGI Group in Shenzhen, P.R. China. MGI is dedicated to develop, manufacture and distribute the genetic instrument, reagents
and device (including DNA genetic analyser but not limited to this) and support the vision of BGI Group to benefit humanity in
BGI Group.


 


INTEND
TO:


		1)	Establish
                                         a long-lasting R&D and commercial relationship in NGS-based molecular diagnostics
                                         (IVD) applications for infectious diseases in Greater China (Mainland China, Hong Kong
                                         and Macau), and,



		2)	Explore
                                         specific collaboration and licensing opportunities in the following areas:



		a)	Demonstrate
                                         and publish the technical feasibility of using the GEAR BiolT Platform and database in
                                         conjunction with MGl’s BGISeq/MGISeq sequencing technology by



		i)	Sequencing
                                         of about 100 DNA samples from GEAR bacterial isolates provided by Curetis with BGISeq
                                         technology by MGI/BGI Group and data analysis using the GEAR BiolT pipeline by Ares in
                                         collaboration with Prof. Andreas Keller of Saarland University.



		ii)	Sequencing
                                         of a limited number of jointly selected interesting clinical bacterial isolates with
                                         available resistance phenotype information from China with BGISeq by MGI/BGI Group and
                                         data analysis using the GEAR BiolT pipeline by Ares.



		iii)	Have
                                         the results presented by Prof. Andreas Keller at the 12th International Conference on
                                         Genomics (ICG-12) is organized by BGI Group, and will be held in October 26-29, 2017,
                                         in Shenzhen, China.



		b)	Develop
                                         and commercialize a fully automated sample to answer workflow for NGS-based infectious
                                         diseases diagnostics for clinically relevant native sample types,



		i)	by
                                         combining Curetis’ L4 Lysator module with MGl’s SP100 Sample preparation
                                         system or similar modules by MGI likely by means of a specific consumable,



		ii)	by
                                         developing sample preparation protocols for relevant native sample types and showing
                                         feasibility of sequencing of the DNA isolated with such workflows with the BGISeq or
                                         MGISeq sequencers,



 


 


    	2 




    	 



    


		iii)	by
                                         manufacturing of specific consumables required for linking the Curetis’ L4 Lysator
                                         to MGl’s SP100 sample preparation system or similar modules by MGI,



		iv)	by
                                         MGI seeking regulatory clearance as required by the CFDA for such sample-to-answer solution,



		v)	by
                                         entering into an OEM supply and/or licensing agreement allowing MGI to commercialize
                                         worldwide the Curetis L4 Lysator and required consumables for exclusive use with the
                                         BGI or MGI suit of NGS instruments under MGI branding.



		c)	Jointly
                                         develop a broad-spectrum targeted MGISeq NGS IVD assay for infectious disease diagnostics
                                         based on Curetis know-how and the GEAR database and technology



		i)	that
                                         would be designed by use of Curetis know-how and by using the GEAR database and including
                                         proprietary markers of antimicrobial resistance,



		ii)	that
                                         would be designed and developed by MGI for use with MGI SP100, MGISeq, and potentially
                                         the Curetis’ L4 Lysator (MGI OEM version; see 2)b) above),



		iii)	that
                                         would be interpreted by a cloud-based application to be developed by Ares,



		iv)	that
                                         allows for a feedback loop for continuous information back-flow to the GEAR reference
                                         database for continuous further verification and validation of GEAR Markers,



		v)	for
                                         which MGI would be the legal manufacturer, perform regulatory required studies and seek
                                         CFDA approval,



		vi)	that
                                         would be commercialized by MGI/BGI Group in Greater China under appropriate licenses
                                         by Curetis/Ares to MGI for GEAR/Curetis know-how and IP, and by MGI/BGI Group to Ares/Curetis
                                         for inclusion of validating data obtained in the feedback-loop (see 2)c) iii in the GEAR
                                         reference database periodically,



		vii)	that
                                         jointly own the newly enriched portion of GEAR database generated through such feedback-loop
                                         and cross-license of Ares’ analysis apps and MGl’s NGS targeted MGISeq NGS
                                         IVD assay methodology,



		viii)	that
                                         could potentially be distributed by Curetis in one or few other geographies under an
                                         appropriate distribution agreement and responsibility to seek regulatory registration
                                         at the corresponding geographies.



		d)	Explore
                                         opportunities to collaborate in the area of metagenomic sequencing for infectious diseases
                                         diagnosis potentially involving third parties.



		e)	Explore
                                         opportunities to collaborate with the Chinese CDC and the Chinese National GeneBank (CNGB)
                                         in the areas of molecular epidemiology, antibiotic stewardship, and sustainability and
                                         expansion concepts for the GEAR database including NGS applications for public health
                                         use.



		f)	Explore
                                         potential manufacturing and commercial collaborations for Curetis’ portfolio of
                                         molecular diagnostics products acknowledging Curetis’ existing commercial partnerships
                                         in Greater China.



		g)	Explore
                                         BGI Group’s willingness to invest in Curetis as part of potential future PIPE transact
                                         ions or public offerings.


 


 



    	3 




    	 



    


WITH
THE FOLLOWING UNDERSTANDING:


		I.	This
                                         Memorandum of Understanding (MoU) signifies a statement of intent to establish and to
                                         explore collaboration between the parties, but is not a legally binding document.
                                         This MoU does not restrict the rights of either party to enter into collaborative
                                         agreements, contracts or working relationships with other parties;



		II.	This
                                         MoU recognizes the intention of the parties to establish and to explore a relationship
                                         to collaborate in a range of areas and to work together for their mutual benefit;



		III.	The
                                         period covered by this MoU is for 12 months, starting at the date of undersigning, and
                                         will be reviewed thereafter. The MoU may be terminated at any time by any party. In any
                                         cases of discontinuance, the parties will honour agreed commitments either via accepted
                                         arrangements or suitable alternatives negotiated at that point;



		IV.	Notwithstanding
                                         the period covered by the MoU, both parties intend to negotiate and enter into one or
                                         several final agreements as follows (references given below in the sections IV and V
                                         refer to the part MOU Intention - “intend to:”):



		i)	For
                                         the collaboration area described under 2) a) by no later than Sep 08, 2017 and in time
                                         for result presentation by Prof. Andreas Keller or Dr. Andreas Posch at ICG-12 as described
                                         in section 2) a) iii); if there is not enough time to complete this goal, both parties
                                         will jointly agree on the next co-marketing opportunity within 90 days of signing the
                                         MoU.



		ii)	For
                                         the collaboration areas described under 2) b) and 2) c) within 90 days of signing the
                                         MoU.



		V.	The
                                         partners grant each other exclusivity of negotiation for the opportunities described
                                         under 2) a), 2) b) and 2) c) for a period of 90 days starting with the date of execution
                                         of the MoU,



		VI.	The
                                         parties recognize the importance and value of this MoU in promoting their individual
                                         and joint activities. However, each party understands that any activity that includes
                                         reference to the other party must be sent to and be approved by this party before use;



		VII.	The
                                         MoU will be announced through a joint press release (Exhibit A) at the earliest at the
                                         day of signature but no later than Sep 12, 2017, 7 am ET. With exception of the information
                                         of such press release, the content and provisions of this MoU are deemed confidential
                                         information as defined in the Non- Disclosure Agreement between MGI and Curetis dated
                                         Jan 20, 2017.



 


 


    	4 




    	 



    


 


MGI
Tech Co., Ltd


 


By/s/
Hui Jiang


Name:
Hui Jiang

Title: Chief Operation Officer

Date: Sep 11, 2017


 


By/s/
Feng Mu


Name:
Feng Mu

Title: Chief Executive Officer

Date: Sep 11, 2017


 


Curetis
GmbH


 


By/s/
Oliver Schacht


Name:
Oliver Schacht, PhD

Title: Managing Director Curetis GmbH

Date: Sep 12, 2017


 


By/s/
Heiko Schorr


Name:
Heiko Schorr

Title: Managing Director Curetis GmbH

Date: Sep 12, 2017


 


Ares
Genetics GmbH


 


By/s/
Achim Plum


Name:
Dr. Achim Plum

Title: Managing Director Ares Genetics GmbH

Date: Sep 12, 2017


 


By/s/
Andreas E. Posch


Name:
Dr. Andreas E. Posch

Title: Managing Director Ares Genetics GmbH

Date: Sep 12, 2017


 


 


    	5 




    	 



    


 


Exhibit
A: Joint Press Release:


 


 


MGI
and Curetis to Collaborate on NGS-based Infectious

Disease Diagnostics


		-	Broad
                                         collaboration to develop a targeted Next-Generation Sequencing assay for microbial infections



		-	Workflow
                                         for native samples integrating MG/ and Curetis instrumentation



		-	Curetis’
                                         subsidiary Ares Genetics to provide assay design and data interpretation app



Amsterdam,
the Netherlands, and Holzgerlingen, Germany,                           ,
2017; published at 07 am ET -- Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”),
a developer of next -level molecular diagnostic solution s, and MGI, a fully-owned subsidiary of BGI Group, one of the world’s
leading genome sequencing centers headquartered in Shenzhen, Guangdong, P.R. China, today announced that they have signed a Memorandum
of Understanding (MoU) for a broad collaboration to develop targeted Next-Generation Sequencing (NGS) IVD assays for microbial
infections.


The
assay will target a comprehensive panel of pathogens and genetic antibiotic resistance markers and will be applicable to a wide
spectrum of native patient sample types. The intended laboratory workflow will combine the Unyvero L4 Lysator by Curetis with
MGl’s SP100 Sample Preparation System and MGISeq NGS Sequencers to allow fully automated lysis, DNA extraction, NGS library
preparation and sequencing or an integrated work station. The resulting NGS data will be interpreted for pathogen identification
and genetic antibiotic resistance markers by an app as a part of the data analysis software. The app will be developed by Ares
Genetics GmbH, a wholly-owned subsidiary of Curetis GmbH based in Vienna, Austria. The assay will be commercialized by MGI in
Greater China first and potentially by Curetis in other geographies. Financial details were not disclosed.


Under
the terms of the agreement, MGI will provide hardware and chemistry integration and develop an automated workflow as well as manufacture
the targeted NGS assays. MGI will also be in charge of validating the assay and seeking regulatory approval as needed. Curetis
and Ares Genetics will provide expertise in sample preparation technologies, panel design and NGS sequencing assay design using
its GEAR GEnetic Antibiotic Resistance and Susceptibility database. Ares will also develop a data interpretation
application that automates the bioinformatics analysis of the NGS data and supports the interpretation and visualization of NGS
results on pathogens and antibiotic resistance markers detected by the assay to facilitate the deployment of the assay in the
clinical routine. Ares and BGI Group will be supported by Prof. Dr. Andreas Keller from the Center for Bioinformatics at Saarland
University, the leading academic partner in the development of the GEAR.


The
partners entered into a first collaboration agreement under the MoU to assess the feasibility of using MGISeq sequencing data
with the GEAR database. Curetis and MGI expect to enter into further agreements to cover other aspects of the collaboration, e.g.
hardware and chemistry integration, OEM manufacturing and supply, design of panel and assays, and licensing and distribution.


“The
planned collaboration is an excellent example for leveraging Curetis’ molecular microbiology expertise and its solutions
in combination with GEAR, “ said Dr. Achim Plum, CBO of Cur et is and a Managing Director at Ares Genetics. “The synergies
with MGI will turn us into a first mover in NGS- based IVDs for severe microbial infections.” He added that Ares is also
in discussions with other industry players. “This is one of several ways we can capitalize on the tremendous potential of
GEAR.”

 


 



    	6 




    	 



    


“NGS
offers the unique possibility to dissect increasingly complex resistance patterns in microbial pathogens in a single test. However,
this requires smart data interpretation and clinical decision support. BGI Group sequencing technology combined with the GEAR
database allows the translation of NGS technology into meaningful diagnostic applications for complex microbial infections. Therefore,
I am excited to support both companies in this endeavor,” commented Prof. Dr. Keller.


“NGS-based
diagnostics of pathogens and resistances is becoming more and more feasible,” said Dr. Andreas Posch, also a Managing Director
at Ares Genetics. “To this end, panel design and data interpretation are key. That’s where the tremendous data collection
of GEAR and the BioIT expertise of Ares Genetics comes in. Our goa l is to create the next generation of molecular microbiology.”


“Today,
NGS is dominating the sequencing space in genomic research,” said Dr. Hui Jiang, Chief Operation Officer of MGI, “But
it is already entering clinical practice, e.g. in prenatal screening and cancer diagnostics. While it already is a key technology
in infectious disease research today, the unique features of NGS, the technological advances, the workflow integration and automation
as well as the affordability make NGS more and more applicable to the clinical diagnostics of infectious diseases. MGI intends
to be a first mover in this space and is very pleased to work with the Curetis Group.”


###


About
MGI


MGI
(MGI Tech Co., Limited) is a part of BGI Group, one of the world’s largest genomics organizations. BGI Group was founded
in 1999 with the vision of using genomics to benefit humanity and has been growing exponentially since t hen. With a focus on
research and applications in the healthcare, agriculture, conservation, and environmental fields, BGI Group has a proven track
record of innovative, high profile research and operates China National Genome Bank through governmental contracts.


MGI
is dedicated to develop, manufacture and distribute instruments, reagents and devices/assays through innovation and collaboration.
Since its acquisition of CGI (Complete Genomics Incorporation), MGI adsorbed its technologies quickly and developed a serial of
genetic sequencers such as BGISEQl 000, BGISE QS0 0, and MGISEQS0 etc. MGl’s mission is to “Make Great Instrument
and Make It Smart” so as to provide in a real time a digitized panoramic view of a living thing at all time and advance
life science to service genomics, proteomics and beyond.


About
Curetis and Ares Genetics


Founded
in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and
cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter
pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks
with other techniques.


To
date, Curetis has raised EUR 44.3 million in an IPO on Euro next Amsterdam and Euronext Brussels and private equity funds of over
EUR 63.5 million. Furthermore, Curetis has entered into a debt financing facility with EIB for up to EUR 25 million. The company
is based in Holzgerlingen near Stuttgart, Ger many. Curetis collaborates with Heraeus Medical, pharmaceutical companies, and has
entered into several international distribution agreements covering many countries across Europe, the Middle East and Asia.


In
2017, Curetis established Ares Genetics GmbH, a wholly-owned subsidiary of Curetis GmbH in Vienna, Austria. Ares Genetics is dedicated
to maximize the R&D and related scientific and business opportunities of the GEAR assets acquired in 2016 for the entire Curetis
Group.


For
further information, please visit www.curetis.com.


Curetis’
Legal Disclaimer


This
document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form
the basis of any investment decision in Curetis.


The
information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever
kind for the correctness and completeness of the information provided


 


 


    	7 




    	 



    


herein.
Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether
as a result of new information, future events or for other reasons.


This
press release includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking
statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”,
“anticipates”, “expects”, “intends”, “may”, “will”, or “should”,
and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements
involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future
performance.


Curetis’
actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation
to publicly update or revise forward-looking statements, except as may be required by law.


Curetis’
Contact Details


Curetis
GmbH

Max-Eyth-Str. 42

71088 Holzgerlingen, Germany

Tel. +49 7031 49195-10

pr@curetis.com or ir@curetis.com

www.curetis.com - www.unyvero.com


International
Media & Investor Inquiries

akampion

Dr. Ludger Wess / Ines-Regina Buth

Managing Partners

info@akampion.com

Tel. +49 40 88 16 59 64

Tel. +49 30 23 63 27 68


U.S.
Media & Investor Inquiries

The Ruth Group

Lee Roth

lroth@theruthgroup.com

Tel. +1 646 536 7012


 






    	8